Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.

@article{Elam1998EffectOT,
  title={Effect of the novel antiplatelet agent cilostazol on plasma lipoproteins in patients with intermittent claudication.},
  author={Marshall B Elam and James J. Heckman and John Robert Crouse and Donald B. Hunninghake and J. Alan Herd and Michael Davidson and Ian L. Gordon and Enoch Bortey and William P. Forbes},
  journal={Arteriosclerosis, thrombosis, and vascular biology},
  year={1998},
  volume={18 12},
  pages={1942-7}
}
Cilostazol is an antiplatelet agent and vasodilator marketed in Japan for treatment of ischemic symptoms of peripheral vascular disease. It is currently being evaluated in the United States for treatment of symptomatic intermittent claudication (IC). Cilostazol has been shown to improve walking distance in patients with IC. In addition to its reported vasodilator and antiplatelet effects, cilostazol has been proposed to have beneficial effects on plasma lipoproteins. We examined the effect of… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 47 extracted citations

Cilostazol for treatment of cerebral infarction.

Expert opinion on pharmacotherapy • 2018
View 1 Excerpt

References

Publications referenced by this paper.
Showing 1-10 of 21 references

Cilostazol

Y Okuda, K Yukio, Y Kamejiro
Cardiovasc Drug Rev • 1993

Similar Papers

Loading similar papers…